APLM APOLLOMICS INC.

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY.

H.C. Wainwright 26th Annual Global Investment Conference

Format: Company presentation

Presentation Date & Time: Available on demand as of September 9, 2024 at 7:00 am ET

Presenters: Guo-Liang Yu, PhD, Chairman and Chief Executive Officer and Matthew Plunkett, PhD, Chief Financial Officer

Webcast: Click

Management will be available for virtual one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative to request meetings. The Company’s current presentation may be accessed on the Company website on the page under the Investors section.

About  

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ programs include its lead product candidate, vebreltinib, a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort global clinical trial, and uproleselan, a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in a Phase 3 clinical trial in China. For more information, please visit .

Investor Contact:

Eric Ribner

LifeSci Advisors, LLC

(646) 751-4363

 



EN
04/09/2024

Underlying

APLMAPOLLOMICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on APOLLOMICS INC.

 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell L...

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024 Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification FOSTER CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant canc...

September 16, 2024 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics to Present at the H.C. Wainwright 26th Annual Global Invest...

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY. H.C. Wainwright 26th...

September 4, 2024 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Reports First Half 2024 Financial Results and Highlights Ve...

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9 million in cash and cash equivalents as of June 30, 2024; cash runway into the third quarter of 2025 FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...

August 14, 2024 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patie...

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial 43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions FOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficu...

August 13, 2024 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conf...

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the Company management will be presenting at the Canaccord Genuity 44th Annual Growth Conference taking place on August 13-15, 2024 in Boston, MA. Canaccord Genuity 44th Annual Growth Conference Format: Company presentationPresentation Date & T...

August 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch